Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 158 publications
Therapeutic drug monitoring of Janus kinase inhibitors for precision dosing: where do we stand ?
Journal: Expert review of clinical pharmacology
Published: October 16, 2025
Repurpose of Ritlecitinib Reduces Neointima Formation and Enhances Endothelial Recovery Following Vascular Injury.
Journal: bioRxiv : the preprint server for biology
Published: October 03, 2025
Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry
Journal: Se pu = Chinese journal of chromatography
Published: September 24, 2025
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
Journal: American journal of clinical dermatology
Published: September 15, 2025
Adjunctive Intramuscular Corticosteroids for Suboptimal Responders to Ritlecitinib in Alopecia Areata: A Case Series.
Journal: Journal of cutaneous medicine and surgery
Published: August 19, 2025
Erosive oral lichen planus successfully treated with JAK3/TEC inhibitor ritlecitinib: A case report.
Erosive oral lichen planus successfully treated with JAK3/TEC inhibitor ritlecitinib: A case report.
Journal: JAAD case reports
Published: August 11, 2025
Comparative Efficacy of Janus Kinase Inhibitors Indicated for Severe Alopecia Areata: A Bayesian Network Meta-Analysis and Matching-Adjusted Indirect Comparison.
Journal: The Journal of dermatology
Published: August 04, 2025
Disseminated maculopapular drug eruption caused by ritlecitinib in a patient with alopecia areata.
Journal: European journal of dermatology : EJD
Published: July 31, 2025
Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement.
Journal: The Australasian journal of dermatology
Published: July 26, 2025
Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.
Journal: Dermatology and therapy
Published: July 21, 2025
Correction to 'Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study'.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 12, 2025
Effective virtual screening strategy toward JAK3 covalent inhibitors: combining multi‑conformational consensus calculation with covalent docking.
Journal: Molecular diversity
Published: July 08, 2025
Last Updated: 10/31/2025